The spectrum of factor XI deficiency in Southeast China: four recurrent variants can explain most of the deficiencies.


Journal

Orphanet journal of rare diseases
ISSN: 1750-1172
Titre abrégé: Orphanet J Rare Dis
Pays: England
ID NLM: 101266602

Informations de publication

Date de publication:
04 Jun 2024
Historique:
received: 13 02 2024
accepted: 27 05 2024
medline: 5 6 2024
pubmed: 5 6 2024
entrez: 4 6 2024
Statut: epublish

Résumé

Factor XI (FXI) deficiency is an autosomal hemorrhagic disorder characterized by reduced plasma FXI levels. Multiple ancestral variants in the F11 gene have been identified in Ashkenazi Jews and other selected European populations. However, there are few reports of predominant variants in Chinese and/or East Asian populations. The aim of this study is to characterize the genotypes and phenotypes of FXI deficiency and identify the predominant variants. Of the 41 FXI-deficient patients, 39 exhibited severe FXI defects, considerably more than those with partial defects. The APTT levels showed a negative correlation with FXI activity levels (coefficient=-0.584, P < .001). Only nine patients experienced mild bleeding, including one partially defective patient and eight severely defective patients. The majority of patients were referred for preoperative screenings (n = 22) and checkups (n = 14). Genetic analysis revealed that 90% of the patients had genetic defects, with 2, 16, and 19 cases of heterozygous, homozygous, and compound heterozygous patients, respectively. Seventeen variants were detected in the F11 gene (6 novel), including eleven missense variants, four nonsense variants, and two small deletions scattered throughout the F11. Of the 11 missense variants, six have not yet been studied for in vitro expression. Protein modeling analyses indicated that all of these variants disrupted local structural stability by altering side-chain orientation and hydrogen bonds. Nine variants, consisting of three missense and six null variants, were detected with a frequency of two or more. The highest allele frequency was observed in p.Q281* (21.25%), p.W246* (17.50%), p.Y369* (12.50%), and p.L442Cfs*8 (12.50%). The former two were variants specific to East Asia, while the remaining two were southeast China-specific variants. Our population-based cohort demonstrated that no correlation between the level of FXI activity and the bleeding severity in FXI deficiency. Additionally, the prevalence of FXI deficiency may have been underestimated. The nonsense p.Q281* was the most common variant in southeast China, suggesting a possible founder effect.

Sections du résumé

BACKGROUND BACKGROUND
Factor XI (FXI) deficiency is an autosomal hemorrhagic disorder characterized by reduced plasma FXI levels. Multiple ancestral variants in the F11 gene have been identified in Ashkenazi Jews and other selected European populations. However, there are few reports of predominant variants in Chinese and/or East Asian populations. The aim of this study is to characterize the genotypes and phenotypes of FXI deficiency and identify the predominant variants.
RESULTS RESULTS
Of the 41 FXI-deficient patients, 39 exhibited severe FXI defects, considerably more than those with partial defects. The APTT levels showed a negative correlation with FXI activity levels (coefficient=-0.584, P < .001). Only nine patients experienced mild bleeding, including one partially defective patient and eight severely defective patients. The majority of patients were referred for preoperative screenings (n = 22) and checkups (n = 14). Genetic analysis revealed that 90% of the patients had genetic defects, with 2, 16, and 19 cases of heterozygous, homozygous, and compound heterozygous patients, respectively. Seventeen variants were detected in the F11 gene (6 novel), including eleven missense variants, four nonsense variants, and two small deletions scattered throughout the F11. Of the 11 missense variants, six have not yet been studied for in vitro expression. Protein modeling analyses indicated that all of these variants disrupted local structural stability by altering side-chain orientation and hydrogen bonds. Nine variants, consisting of three missense and six null variants, were detected with a frequency of two or more. The highest allele frequency was observed in p.Q281* (21.25%), p.W246* (17.50%), p.Y369* (12.50%), and p.L442Cfs*8 (12.50%). The former two were variants specific to East Asia, while the remaining two were southeast China-specific variants.
CONCLUSION CONCLUSIONS
Our population-based cohort demonstrated that no correlation between the level of FXI activity and the bleeding severity in FXI deficiency. Additionally, the prevalence of FXI deficiency may have been underestimated. The nonsense p.Q281* was the most common variant in southeast China, suggesting a possible founder effect.

Identifiants

pubmed: 38835089
doi: 10.1186/s13023-024-03235-5
pii: 10.1186/s13023-024-03235-5
doi:

Substances chimiques

Factor XI 9013-55-2

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

224

Informations de copyright

© 2024. The Author(s).

Références

Puy C, Rigg RA, McCarty OJT. The hemostatic role of factor XI. Thromb Res. 2016;141:S8–11. https://doi.org/10.1016/S0049-3848(16)30354-1 .
doi: 10.1016/S0049-3848(16)30354-1 pubmed: 27207433 pmcid: 6135087
Mohammed BM, Matafonov A, Ivanov I, Sun M-f, Cheng Q, Dickeson SK, et al. An update on factor XI structure and function. Thromb Res. 2018;161:94–105. https://doi.org/10.1016/j.thromres.2017.10.008 .
doi: 10.1016/j.thromres.2017.10.008 pubmed: 29223926
Lewandowska MD, Connors JM, Factor XI, Deficiency. Hematol Oncol Clin North Am. 2021;35(6):1157–69. https://doi.org/10.1016/j.hoc.2021.07.012 .
doi: 10.1016/j.hoc.2021.07.012 pubmed: 34535287
Hayakawa Y, Tamura S, Suzuki N, Odaira K, Tokoro M, Kawashima F, et al. Essential role of a carboxyl-terminal α-helix motif in the secretion of coagulation factor XI. J Thromb Haemost. 2021;19(4):920–30. https://doi.org/10.1111/jth.15242 .
doi: 10.1111/jth.15242 pubmed: 33421272
Rimoldi V, Paraboschi EM, Menegatti M, Peyvandi F, Salomon O, Duga S, et al. Molecular investigation of 41 patients affected by coagulation factor XI deficiency. Haemophilia. 2018;24(2):E50–5. https://doi.org/10.1111/hae.13378 .
doi: 10.1111/hae.13378 pubmed: 29178608
Ahmadinejad M, Alavi S, Ebadi M, Rashidi A, Tabatabaei M, Rezvani A. Combined high molecular weight Kininogen and factor XI deficiency. Haemophilia. 2016;22(1):E60–1. https://doi.org/10.1111/hae.12835 .
doi: 10.1111/hae.12835 pubmed: 26572243
Santoro C, Di Mauro R, Baldacci E, De Angelis F, Abbruzzese R, Barone F, et al. Bleeding phenotype and correlation with factor XI (FXI) activity in congenital FXI deficiency: results of a retrospective study from a single centre. Haemophilia. 2015;21(4):496–501. https://doi.org/10.1111/hae.12628 .
doi: 10.1111/hae.12628 pubmed: 25623511
Wheeler AP, Gailani D. Why factor XI deficiency is a clinical concern. Expert Rev Hematol. 2016;9(7):629–37. https://doi.org/10.1080/17474086.2016.1191944 .
doi: 10.1080/17474086.2016.1191944 pubmed: 27216469 pmcid: 4950943
Ganor RS, Harats D, Schiby G, Gailani D, Levkovitz H, Avivi C, et al. Factor XI Deficiency protects against atherogenesis in apolipoprotein E/Factor XI double knockout mice. Arterioscler Thromb Vasc Biol. 2016;36(3):475–81. https://doi.org/10.1161/atvbaha.115.306954 .
doi: 10.1161/atvbaha.115.306954 pmcid: 4785893
Kossmann S, Lagrange J, Jaeckel S, Jurk K, Ehlken M, Schoenfelder T, et al. Platelet-localized FXI promotes a vascular coagulation-inflammatory circuit in arterial hypertension. Sci Transl Med. 2017;9(375). https://doi.org/10.1126/scitranslmed.aah4923 .
Sillen M, Declerck PJ. Thrombin activatable fibrinolysis inhibitor (TAFI): an updated narrative review. Int J Mol Sci. 2021;22(7). https://doi.org/10.3390/ijms22073670 .
Xie H, Liu M, Zou A, Xie Y, Ye J. A novel mutation (Leu60Pro) in a Chinese pedigree with hereditary factor XI deficiency. Blood Coagul Fibrinolysis. 2021;32(6):401–5. https://doi.org/10.1097/mbc.0000000000001010 .
doi: 10.1097/mbc.0000000000001010 pubmed: 33443931
den Dunnen JT, Dalgleish R, Maglott DR, Hart RK, Greenblatt MS, McGowan-Jordan J, et al. HGVS recommendations for the description of sequence variants: 2016 update. Hum Mutat. 2016;37(6):564–9. https://doi.org/10.1002/humu.22981 .
doi: 10.1002/humu.22981
Seligsohn U. Factor XI deficiency in humans. J Thromb Haemost. 2009;7:84–7. https://doi.org/10.1111/j.1538-7836.2009.03395.x .
doi: 10.1111/j.1538-7836.2009.03395.x pubmed: 19630775
Lippi G, Pasalic L, Favaloro EJ. Detection of mild inherited disorders of blood coagulation: current options and personal recommendations. Expert Rev Hematol. 2015;8(4):527–42. https://doi.org/10.1586/17474086.2015.1039978 .
doi: 10.1586/17474086.2015.1039978 pubmed: 25912928
Kuder H, Dickeson SK, Brooks MB, Kehl A, Müller E, Gailani D, et al. A common missense variant causing factor XI Deficiency and increased bleeding tendency in Maine Coon cats. Genes. 2022;13(5). https://doi.org/10.3390/genes13050792 .
Jiang S, Chen Y, Liu M, Zeng M, Yang L, Jin Y, et al. Gene Variants in two families with inherited coagulation factor XI Deficiency and Identification of mutations. Acta Haematol. 2023;146(2):106–16. https://doi.org/10.1159/000528583 .
doi: 10.1159/000528583 pubmed: 36543159
Kravtsov DV, Wu WM, Meijers JCM, Sun MF, Blinder MA, Dang TP, et al. Dominant factor XI deficiency caused by mutations in the factor XI catalytic domain. Blood. 2004;104(1):128–34. https://doi.org/10.1182/blood-2003-10-3530 .
doi: 10.1182/blood-2003-10-3530 pubmed: 15026311
Shao Y, Cao Y, Lu Y, Dai J, Ding Q, Wang X, et al. Clinical manifestations and mutation spectrum of 57 subjects with congenital factor XI deficiency in China. Blood Cells Mol Dis. 2016;58:29–34. https://doi.org/10.1016/j.bcmd.2016.01.004 .
doi: 10.1016/j.bcmd.2016.01.004 pubmed: 27067486
Au WY, Cheung JW, Lam CCK, Kwong YL. Two factor XI mutations in a Chinese family with factor XI deficiency. Am J Hematol. 2003;74(2):136–8. https://doi.org/10.1002/ajh.10396 .
doi: 10.1002/ajh.10396 pubmed: 14508802
Lin F, Weng MS, Wu JR, Fang SH, Yang LY. Gene variants in four pedigrees with hereditary coagulation factor XI deficiency and one novel mutation identification. Blood Coagul Fibrinolysis. 2020;31(2):160–4. https://doi.org/10.1097/mbc.0000000000000861 .
doi: 10.1097/mbc.0000000000000861 pubmed: 31815744
Lin HY, Lin CY, Hung MH, Kuo SF, Lin JS, Shen MC. Characterization of hereditary factor XI deficiency in Taiwanese patients: identification of three novel and two common mutations. Int J Hematol. 2020;112(2):169–75. https://doi.org/10.1007/s12185-020-02883-0 .
doi: 10.1007/s12185-020-02883-0 pubmed: 32333264
Rosenthal RL, Dreskin OH, Rosenthal N. New hemophilia-like disease caused by deficiency of a third plasma thromboplastin factor. Proc Soc Exp Biol Med. 1953;82(1):171–4.
pubmed: 13037836
Dorgalaleh A, Bahraini M, Shams M, Parhizkari F, Dabbagh A, Naderi T, et al. Molecular basis of rare congenital bleeding disorders. Blood Rev. 2023;59. https://doi.org/10.1016/j.blre.2022.101029 .
Asselta R, Paraboschi EM, Rimoldi V, Menegatti M, Peyvandi F, Salomon O, et al. Exploring the global landscape of genetic variation in coagulation factor XI deficiency. Blood. 2017;130(4):E1–6. https://doi.org/10.1182/blood-2017-04-780148 .
doi: 10.1182/blood-2017-04-780148 pubmed: 28615222
Esteban J, de la Morena-Barrio ME, Salloum-Asfar S, Padilla J, Minano A, Roldan V, et al. High incidence of FXI deficiency in a Spanish Town caused by 11 different mutations and the first duplication of < i > F11: results from the Yecla study. Haemophilia. 2017;23(6):E488–96. https://doi.org/10.1111/hae.13356 .
doi: 10.1111/hae.13356 pubmed: 28960694
Shpilberg O, Peretz H, Zivelin A, Yatuv R, Chetrit A, Kulka T, et al. One of the two common mutations causing factor XI deficiency in Ashkenazi jews (type II) is also prevalent in Iraqi jews, who represent the ancient gene pool of jews. Blood. 1995;85(2):429–32. https://doi.org/10.1182/blood.V85.2.429.bloodjournal852429 .
doi: 10.1182/blood.V85.2.429.bloodjournal852429 pubmed: 7811996
Zivelin A, Bauduer F, Ducout L, Peretz H, Rosenberg N, Yatuv R, et al. Factor XI deficiency in French basques is caused predominantly by an ancestral Cys38Arg mutation in the factor XI gene. Blood. 2002;99(7):2448–54. https://doi.org/10.1182/blood.V99.7.2448 .
doi: 10.1182/blood.V99.7.2448 pubmed: 11895778
Bolton-Maggs PHB, Peretz H, Butler R, Mountford R, Keeney S, Zacharski L, et al. A common ancestral mutation (C128X) occurring in 11 non-jewish families from the UK with factor XI deficiency. J Thromb Haemost. 2004;2(6):918–24. https://doi.org/10.1111/j.1538-7836.2004.00723.x .
doi: 10.1111/j.1538-7836.2004.00723.x pubmed: 15140127
Quélin F, Trossaërt A, Sigaud M, Mazancourt PDE, Fressinaud E. Molecular basis of severe factor XI deficiency in seven families from the west of France.: seven novel mutations, including an ancient Q88X mutation. J Thromb Haemost. 2004;2(1):71–6. https://doi.org/10.1111/j.1538-7836.2004.00554.x .
doi: 10.1111/j.1538-7836.2004.00554.x pubmed: 14717969
Kim J, Song J, Lyu CJ, Kim YR, Oh SH, Choi YC, et al. Population-specific spectrum of the F11 mutations in koreans: evidence for a founder effect. Clin Genet. 2012;82(2):180–6. https://doi.org/10.1111/j.1399-0004.2011.01732.x .
doi: 10.1111/j.1399-0004.2011.01732.x pubmed: 21668437

Auteurs

Ke Zhang (K)

Department of Clinical Laboratory, Key Laboratory of Clinical Laboratory Diagnosis and Translational Research of Zhejiang Province, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, China.

Langyi Qin (L)

Department of Clinical Laboratory, Key Laboratory of Clinical Laboratory Diagnosis and Translational Research of Zhejiang Province, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, China.

Fei Xu (F)

Department of Clinical Laboratory, Key Laboratory of Clinical Laboratory Diagnosis and Translational Research of Zhejiang Province, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, China.

Longying Ye (L)

Department of Clinical Laboratory, Key Laboratory of Clinical Laboratory Diagnosis and Translational Research of Zhejiang Province, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, China.

Mengzhen Wen (M)

Department of Clinical Laboratory, Key Laboratory of Clinical Laboratory Diagnosis and Translational Research of Zhejiang Province, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, China.

Jingye Pan (J)

Department of Intensive Care Unit, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, China.

Lihong Yang (L)

Department of Clinical Laboratory, Key Laboratory of Clinical Laboratory Diagnosis and Translational Research of Zhejiang Province, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, China.

Mingshan Wang (M)

Department of Clinical Laboratory, Key Laboratory of Clinical Laboratory Diagnosis and Translational Research of Zhejiang Province, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, China. wywms@126.com.

Haixiao Xie (H)

Department of Clinical Laboratory, Key Laboratory of Clinical Laboratory Diagnosis and Translational Research of Zhejiang Province, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, China. wyxiehaixiao@163.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH